How do I install the Endo Trial Cabergoline Modest Igf1 Mild skill?

Run npx skillmds@latest add dromlakhani/endo-trial-cabergoline-modest-igf1-mild in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Endo Trial Cabergoline Modest Igf1 Mild safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Endo Trial Cabergoline Modest Igf1 Mild?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Endo Trial Cabergoline Modest Igf1 Mild free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Endo Trial Cabergoline Modest Igf1 Mild?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Trial Cabergoline Modest Igf1 Mild by dromlakhani

Name: Endo Trial Cabergoline Modest Igf1 Mild
Rating: 4.666666666666667 (3 reviews)
Author: dromlakhani

Endo Trial Cabergoline Modest Igf1 Mild

Suggests a trial of a dopamine agonist, usually cabergoline, as initial adjuvant therapy in patients with only modest IGF-1 elevations and mild GH excess symptoms after surgery. Use when postoperative IGF-1 is mildly elevated and symptoms of GH excess are mild.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Trial of cabergoline as initial adjuvant therapy for modest disease

STEP 1 — Gather Information

Confirm postoperative status (typically ≥12 weeks after transsphenoidal surgery). Measure serum IGF-1 (age‑adjusted) and random GH. Assess for mild GH‑excess symptoms (e.g., fatigue, headache, mild sweating) and absence of severe features (visual field defects, cardiomegaly, pronounced acral changes).

STEP 2 — Rule In / Rule Out

Rule in modest disease if IGF-1 is ≤1.5× ULN and GH is <1.0 µg/L with only mild symptoms. Rule out if IGF-1 >1.5× ULN, GH ≥1.0 µg/L, or moderate‑to‑severe symptoms (significant sweating, arthralgias, sleep apnea, cardiomyopathy) — proceed to SRL or pegvisomant per 5.2.

STEP 3 — Classify or Stratify

Classify as “modest biochemical disease” when criteria above are met. Stratify further by prolactin level: if mildly elevated, cabergoline may address both GH and prolactin; if normal, cabergoline still appropriate as dopamine agonist trial.

STEP 4 — Decide

Initiate cabergoline at a low dose (e.g., 0.5 mg twice weekly) and titrate based on tolerance and response. Schedule IGF-1 and symptom assessment at 12 weeks; if IGF-1 normalizes or improves ≥20% and symptoms improve, continue; otherwise escalate to SRL or pegvisomant per 5.2/5.7.

Clinical Guardrails / Mimics / Pitfalls

Do not use cabergoline as monotherapy for moderate‑to‑severe disease; avoid high doses (>2 mg/week) without cardiac valve surveillance due to valvulopathy risk. Do not initiate in pregnancy without obstetric counseling. Ensure IGF-1 assay consistency; do not rely on random GH alone for efficacy assessment.

Concrete Clinical Example

A 48‑year‑old woman undergoes transsphenoidal resection for a macroadenoma. Twelve weeks post‑op IGF-1 is 1.3× ULN, random GH 0.6 µg/L, she reports mild intermittent headaches and fatigue, no visual field deficits. Cabergoline 0.5 mg twice weekly is started. At 12 weeks IGF-1 falls to 1.0× ULN and headaches improve; therapy is continued with monitoring every 6 months.

Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700

---name: endo-trial-cabergoline-modest-igf1-milddescription: Suggests a trial of a dopamine agonist, usually cabergoline, as initial adjuvant therapy in patients with only modest IGF-1 elevations and mild GH excess symptoms after surgery. Use when postoperative IGF-1 is mildly elevated and symptoms of GH excess are mild.---# Trial of cabergoline as initial adjuvant therapy for modest disease## STEP 1 — Gather InformationConfirm postoperative status (typically ≥12 weeks after transsphenoidal surgery). Measure serum IGF-1 (age‑adjusted) and random GH. Assess for mild GH‑excess symptoms (e.g., fatigue, headache, mild sweating) and absence of severe features (visual field defects, cardiomegaly, pronounced acral changes).## STEP 2 — Rule In / Rule OutRule in modest disease if IGF-1 is ≤1.5× ULN and GH is <1.0 µg/L with only mild symptoms. Rule out if IGF-1 >1.5× ULN, GH ≥1.0 µg/L, or moderate‑to‑severe symptoms (significant sweating, arthralgias, sleep apnea, cardiomyopathy) — proceed to SRL or pegvisomant per 5.2.## STEP 3 — Classify or StratifyClassify as “modest biochemical disease” when criteria above are met. Stratify further by prolactin level: if mildly elevated, cabergoline may address both GH and prolactin; if normal, cabergoline still appropriate as dopamine agonist trial.## STEP 4 — DecideInitiate cabergoline at a low dose (e.g., 0.5 mg twice weekly) and titrate based on tolerance and response. Schedule IGF-1 and symptom assessment at 12 weeks; if IGF-1 normalizes or improves ≥20% and symptoms improve, continue; otherwise escalate to SRL or pegvisomant per 5.2/5.7.## Clinical Guardrails / Mimics / PitfallsDo not use cabergoline as monotherapy for moderate‑to‑severe disease; avoid high doses (>2 mg/week) without cardiac valve surveillance due to valvulopathy risk. Do not initiate in pregnancy without obstetric counseling. Ensure IGF-1 assay consistency; do not rely on random GH alone for efficacy assessment.## Concrete Clinical ExampleA 48‑year‑old woman undergoes transsphenoidal resection for a macroadenoma. Twelve weeks post‑op IGF-1 is 1.3× ULN, random GH 0.6 µg/L, she reports mild intermittent headaches and fatigue, no visual field deficits. Cabergoline 0.5 mg twice weekly is started. At 12 weeks IGF-1 falls to 1.0× ULN and headaches improve; therapy is continued with monitoring every 6 months.**Source:** Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700

Frequently asked questions